EBMT activity survey 2004 and changes in disease indication over the past 15 years.
Reads0
Chats0
TLDR
The decline in HSCT for chronic myeloid leukemia appears to level off for the first time since 1999 and leukemias for allogeneic and lymphoproliferative disorders for autologous HSCT continue to increase.Abstract:
This fifteenth annual European Group for Blood and Marrow Transplantation activity report lists the transplant activity in Europe in 2004 and documents the changes in indication over the past 15 years. In 2004, there were 22 216 first hematopoetic stem cells (HSCT), 7407 allogeneic (33%), 14 809 autologous (67%) and 4378 additional re- or multiple transplants reported from 592 centres in 38 European and five affiliated countries. Main indications were leukemias (7045 (32%; 78% allogeneic)); lymphomas (12 310 (55%; 94% autologous)); solid tumors (1759 (8%; 93% autologous)) and nonmalignant disorders (1015 (5%; 92% allogeneic)). In comparison, 145 teams from 20 countries performed 4234 HSCT (2137 allogeneic, 50%; 2097 autologous, 50%) in 1990. The overall increase was accompanied by major changes. Stem cell source changed from bone marrow to peripheral blood. More than one-third of allogeneic HSCT are now from unrelated donors. Reduced intensity conditioning is employed for one-third of allogeneic HSCT. Leukemias for allogeneic and lymphoproliferative disorders for autologous HSCT continue to increase. The decline in HSCT for chronic myeloid leukemia appears to level off for the first time since 1999. These data are informative for patient counselling and decision making for health care professionals.read more
Citations
More filters
Journal ArticleDOI
Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.
John F. DiPersio,Ivana N. Micallef,Patrick J. Stiff,Brian J. Bolwell,Richard T. Maziarz,Eric D. Jacobsen,Auayporn Nademanee,John M. McCarty,Gary Bridger,Gary Calandra +9 more
TL;DR: Plerixafor and G- CSF were well tolerated and resulted in a significantly higher proportion of patients with non-Hodgkin's lymphoma achieving the optimal CD34+ cell target for transplantation in fewer apheresis days, compared with G-CSF alone.
Journal ArticleDOI
Effect of Age on Outcome of Reduced-Intensity Hematopoietic Cell Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission or With Myelodysplastic Syndrome
Brian McClune,Daniel J. Weisdorf,Tanya L. Pedersen,Gisela Tunes da Silva,Martin S. Tallman,Jorge Sierra,John F. DiPersio,Armand Keating,Robert Peter Gale,Biju George,Vikas Gupta,Theresa Hahn,Luis Isola,Madan Jagasia,Hillard M. Lazarus,David Marks,Richard T. Maziarz,Edmund K. Waller,Christopher Bredeson,Sergio Giralt +19 more
TL;DR: It is concluded that older age alone should not be considered a contraindication to HCT, as similar outcomes observed in older patients.
Journal ArticleDOI
Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System.
Yoshiko Atsuta,Ritsuro Suzuki,Ayami Yoshimi,Hisashi Gondo,Junji Tanaka,Akira Hiraoka,Koji Kato,Ken Tabuchi,Masahiro Tsuchida,Yasuo Morishima,Makoto Mitamura,Keisei Kawa,Shunichi Kato,Tokiko Nagamura,Minoko Takanashi,Yoshihisa Kodera +15 more
TL;DR: JSHCT played a central role in developing the “Transplant Registry Unified Management Program (TRUMP)” to enable transplantation institutes to manage patient information with emphases on convenience to institutes, safety of patient information, and quality of data management.
Journal ArticleDOI
Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS.
Selina M. Luger,Olle Ringdén,Mei-Jie Zhang,Waleska S. Pérez,Michael R. Bishop,Martin Bornhäuser,Christopher Bredeson,Mitchell S. Cairo,Edward A. Copelan,Robert Peter Gale,Sergio Giralt,Zafer Gulbas,Vikas Gupta,Gregory A. Hale,Hillard M. Lazarus,Victor Lewis,Michael Lill,Philip L. McCarthy,Daniel J. Weisdorf,Michael A. Pulsipher +19 more
TL;DR: It is suggested that higher regimen intensity may contribute to optimal survival in patients with AML/MDS, suggesting roles for both regimen intensity and graft vs leukemia in these diseases.
Journal ArticleDOI
Effect of Inpatient Palliative Care During Hematopoietic Stem-Cell Transplant on Psychological Distress 6 Months After Transplant: Results of a Randomized Clinical Trial.
Areej El-Jawahri,Lara Traeger,Joseph A. Greer,Harry VanDusen,Sarah Fishman,Thomas W. LeBlanc,William F. Pirl,Vicki A. Jackson,Jason Telles,Alison M. Rhodes,Zhigang Li,Thomas R. Spitzer,Steven L. McAfee,Yi Bin Chen,Jennifer S. Temel +14 more
TL;DR: Inpatient palliative care integrated with transplant care leads to improvements in depression and PTSD symptoms at 6 months post-transplant, partially accounts for the effect of the intervention on these outcomes.
References
More filters
Journal ArticleDOI
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
Brian J. Druker,Moshe Talpaz,Debra Resta,Bin Peng,Elisabeth Buchdunger,John Ford,Nicholas B. Lydon,Hagop M. Kantarjian,Renaud Capdeville,Sayuri Ohno-Jones,Charles L. Sawyers +10 more
TL;DR: STI571 is well tolerated and has significant antileukemic activity in patients with CML in whom treatment with interferon alfa had failed and demonstrates the potential for the development of anticancer drugs based on the specific molecular abnormality present in a human cancer.
Journal ArticleDOI
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
Stephen G. O'Brien,François Guilhot,Richard A. Larson,Insa Gathmann,Michele Baccarani,Francisco Cervantes,Jan J. Cornelissen,Thomas Fischer,Andreas Hochhaus,Timothy P. Hughes,Klaus Lechner,Johan Lanng Nielsen,Philippe Rousselot,Josy Reiffers,Giuseppe Saglio,John D. Shepherd,Bengt Simonsson,Alois Gratwohl,John M. Goldman,Hagop M. Kantarjian,Kerry Taylor,Gregor Verhoef,Ann E. Bolton,Renaud Capdeville,Brian J. Druker +24 more
TL;DR: Imatinib was superior to interferon alfa plus low-dose cytarabine as first-line therapy in newly diagnosed chronic-phase CML and was better tolerated than combination therapy.
Journal ArticleDOI
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.
Michel Attal,Jean-Luc Harousseau,Anne-Marie Stoppa,Jean-Jacques Sotto,Jean-Gabriel Fuzibet,Jean-François Rossi,Philippe Casassus,Hervé Maisonneuve,Thierry Facon,Norbert Ifrah,Catherine Payen,Régis Bataille +11 more
TL;DR: The response rate among the patients who received high-dose therapy was 81 percent, whereas it was 57 percent in the group treated with conventional chemotherapy (P<0.001).
Journal ArticleDOI
Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma
Thierry Philip,Cesare Guglielmi,Anton Hagenbeek,Riet Somers,H. Van der Lelie,Dominique Bron,Pieter Sonneveld,Christian Gisselbrecht,Jean-Yves Cahn,Jean Luc Harousseau +9 more
TL;DR: Treatment with high-dose chemotherapy and autologous bone marrow transplantation increases event-free and overall survival in patients with chemotherapy-sensitive non-Hodgkin's lymphoma in relapse.